Movement Alert|10x Genomics, Inc. Intraday Decline 5.1%, analyst target cuts continue to weigh after earnings

Market Focus11-10

On November 10, 10x Genomics, Inc. fell 5.1% in Regular Trading, trading at $62.6 per share, with turnover of $6.8689 million.

The move followed continued pressure from post-earnings analyst target reductions, even after the company reported results above expectations and raised its full-year revenue outlook.

In its latest quarterly report, 10x Genomics, Inc. posted a Q3 loss of $0.15 per share, better than estimates for a $0.25 to $0.27 loss, while revenue of $150.667 million exceeded expectations near $147.9 million to $148.0 million. The company also lifted full-year revenue guidance to $625 million-$635 million from $610 million-$630 million, above the consensus estimate of $620.8 million. However, several firms subsequently lowered price targets, including UBS to $61 from $90, Barclays to $70 from $110, and BofA to $65 from $80, reflecting continued caution on growth durability and valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment